Michael Babich

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 3

Top Topics

Randomized Controlled Trial

Top Venues

OncoTargets and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Weijie Ma, Jie Zeng, Dennis J Montoya, Kyra Toomey, Chihong Zhou, Shuai Chen, Dingning Liu, Michael Babich, James A Radosevich, Tianhong Li
Labyrinthin Expression Is Associated with Poor Prognosis in Patients with Non-Small-Cell Lung Cancer. Cancers 15 (3) (2023)
Weijie Ma, Jie Zeng, Dennis J Montoya, Kyra Toomey, Chihong Zhou, Shuai Chen, Dingning Liu, Michael Babich, James A Radosevich, Tianhong Li
Labyrinthin Expression Is Associated with Poor Prognosis in Patients with Non-Small-Cell Lung Cancer. Cancers 15 (3) (2023)
James A Radosevich, Michael Babich
Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer. OncoTargets and therapy 12 (2019)